Patents Assigned to Choongwae Pharma Corporation
  • Publication number: 20100069333
    Abstract: The invention provides ?-mimetic structures and a chemical library relating thereto. Additionally, the invention provides methods wherein ?-mimetic compounds are used to treat cancer stem cells.
    Type: Application
    Filed: November 11, 2009
    Publication date: March 18, 2010
    Applicant: Choongwae Pharma Corporation
    Inventor: Michael Kahn
  • Patent number: 7671054
    Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    Type: Grant
    Filed: October 15, 2007
    Date of Patent: March 2, 2010
    Assignee: Choongwae Pharma Corporation
    Inventors: Sung Hwan Moon, Jae Uk Chung, Sung Chan Lee, Masakatsu Eguchi, Michael Kahn, Kwang Won Jeong, Cu Nguyen, Soo Jin Lee
  • Patent number: 7662960
    Abstract: Conformationally constrained compounds of structure: which mimic the secondary structure of ?-strand regions of biologically active peptides and proteins are disclosed. Such ?-strand mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents that inhibit protease, kinase and the like. Libraries containing the ?-strand mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: February 16, 2010
    Assignee: Choongwae Pharma Corporation
    Inventors: Michael Kahn, Masakatsu Eguchi, Sung Hwan Moon, Jae Uk Chung
  • Patent number: 7585862
    Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: September 8, 2009
    Assignee: Choongwae Pharma Corporation
    Inventors: Sung Hwan Moon, Jae Uk Chung, Sung Chan Lee, Masakatsu Eguchi, Michael Kahn, Kwang Won Jeong, Cu Nguyen
  • Publication number: 20090215783
    Abstract: The present invention relates to composition and methods for inducing or inhibiting differentiation of stem cells. The invention also relates to applications in the treatment of medical conditions, e.g., osteoporosis, bone fracture, bone injuries, myocardiac infarction, cardiomyopathy, degenerative muscle diseases, myopathy, and urinary incontinence.
    Type: Application
    Filed: May 30, 2007
    Publication date: August 27, 2009
    Applicant: CHOONGWAE PHARMA CORPORATION
    Inventor: Se Woong Oh
  • Patent number: 7576084
    Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    Type: Grant
    Filed: April 16, 2004
    Date of Patent: August 18, 2009
    Assignee: Choongwae Pharma Corporation
    Inventors: Sung Hwan Moon, Jae Uk Chung, Sung Chan Lee, Masakatsu Eguchi, Michael Kahn, Kwang Won Jeong, Cu Nguyen
  • Patent number: 7566711
    Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    Type: Grant
    Filed: April 15, 2005
    Date of Patent: July 28, 2009
    Assignee: Choongwae Pharma Corporation
    Inventors: Sung Hwan Moon, Jae Uk Chung, Sung Chan Lee, Masakatsu Eguchi, Michael Kahn, Kwang Won Jeong, Cu Nguyen, Soo Jin Lee
  • Patent number: 7563825
    Abstract: Methods and agents are disclosed for modulating the interaction of ?-catenin or ?-catenin with CBP or p300. Agents that increase the binding of CBP to ?-catenin are associated with enhancing the ?-catenin-related proliferation of adult stem cells, including hematopoietic stem cells, neural stem cells, skin stem cells, and pancreatic stem cells.
    Type: Grant
    Filed: March 16, 2006
    Date of Patent: July 21, 2009
    Assignee: Choongwae Pharma Corporation
    Inventor: Michael Kahn
  • Patent number: 7531320
    Abstract: The present invention provides compounds and methods for modulating transcription activated by ?-catenin/TCF, such as the selective inhibition of genes targeted by the Wnt/?-catenin pathway.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: May 12, 2009
    Assignee: Choongwae Pharma Corporation
    Inventors: Michael Kahn, SeWoong Oh, DaeHoon Kim, JongRyul Ha, Katayoon Hojjati-Emami
  • Patent number: 7495126
    Abstract: This invention relates to a method for preparing tetrafluorobenzyl-5-aminosalicylic acid derivative and its pharmaceutically acceptable salt compounds. In particular, this invention relates to a method for preparing tetrafluorobenzyl-5-aminosalicylic acid derivative and its pharmaceutically acceptable salts by using tetrafluorobenzilidine-5-aminosalicylic acid derivative as an intermediate.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: February 24, 2009
    Assignee: Choongwae Pharma Corporation
    Inventors: Tae-Seop Hwang, Hyun-Gyu Kim
  • Publication number: 20080167492
    Abstract: This invention relates to a method for preparing tetrafluorobenzyl-5-aminosalicylic acid derivative and its pharmaceutically acceptable salt compounds. In particular, this invention relates to a method for preparing tetrafluorobenzyl-5-aminosalicylic acid derivative and its pharmaceutically acceptable salts by using tetrafluorobenzilidine-5-aminosalicylic acid derivative as an intermediate.
    Type: Application
    Filed: May 25, 2006
    Publication date: July 10, 2008
    Applicant: Choongwae Pharma Corporation
    Inventors: Tae-Seop Hwang, Hyun-Gyu Kim
  • Patent number: 7232822
    Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    Type: Grant
    Filed: March 17, 2004
    Date of Patent: June 19, 2007
    Assignee: Choongwae Pharma Corporation
    Inventors: Sung Hwan Moon, Jae Uk Chung, Sung Chan Lee, Masakatsu Eguchi, Michael Kahn, Kwang Won Jeong, Cu Nguyen
  • Patent number: 7205418
    Abstract: The present invention relates to new process for preparing as a key chiral intermediate compound of formula (I) obtained from an epoxy-?-hydroxy carboxylic acid ester of formula (II) prepared from epoxide compound of formula (III), in which said compound of formula (I) is useful for preparing the therapeutic agent for hyperlipidemia, such as Astrovastatin and Fluvastatin. Wherein R1 denotes a hydrogen atom, alkyl, aryl or alkylaryl, R2 and R3 which can be identical or different, are a lower alkyl or phenyl and are capable of forming a six-membered ring, R4 stands for hydroxy, amino, alkylamino, azido, cyano, halogeno, aryloxy, alkyloxy, arylalkyloxy, alkyl, alkenyl, aryl, or aminomethyl, etc.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: April 17, 2007
    Assignee: Choongwae Pharma Corporation
    Inventors: Inhee Lee, Seungjoo Lee
  • Patent number: 7186751
    Abstract: The disclosure concerns an injectable composition of paclitaxel, more particularly, an injectable composition of paclitaxel having excellent anticancer effect comprising solubilizer such as polyoxyl hydrogenated castor oil, anhydrous ethanol and stabilizer such as N-acetyl amino acid. The injectable compositions of paclitaxel provide a medical effect higher than that of the known compositions showing not only a lower toxicity but also superior solubility of paclitaxel and stability at room temperature, thus enabling venous injection by having fine particles.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: March 6, 2007
    Assignee: Choongwae Pharma Corporation
    Inventors: Woo-Young Lee, Sang-Heon Lee, Kye-Hyun Kim
  • Publication number: 20070043052
    Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    Type: Application
    Filed: April 15, 2005
    Publication date: February 22, 2007
    Applicant: Choongwae Pharma Corporation
    Inventors: Sung Moon, Jae Chung, Sung Lee, Masakatsu Eguchi, Michael Kahn, Kwang Jeong, Cu Nguyen, Soo Lee
  • Publication number: 20070021431
    Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    Type: Application
    Filed: March 17, 2004
    Publication date: January 25, 2007
    Applicant: Choongwae Pharma Corporation
    Inventors: Sung Moon, Jae Chung, Sung Lee, Masakatsu Eguchi, Michael Kahn, Kwang Jeong, Cu Nguyen
  • Publication number: 20070021425
    Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    Type: Application
    Filed: April 16, 2004
    Publication date: January 25, 2007
    Applicant: Choongwae Pharma Corporation
    Inventors: Sung Moon, Jae Chung, Sung Lee, Masakatsu Eguchi, Michael Kahn, Kwang Jeong, Cu Nguyen
  • Publication number: 20060084655
    Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
    Type: Application
    Filed: October 4, 2005
    Publication date: April 20, 2006
    Applicant: Choongwae Pharma Corporation
    Inventors: Sung Moon, Jae Chung, Sung Lee, Masakatsu Eguchi, Michael Kahn, Kwang Jeong, Cu Nguyen
  • Publication number: 20050059628
    Abstract: The present invention provides compounds and methods for modulating transcription activated by ?-catenin/TCF, such as the selective inhibition of genes targeted by the Wnt/?-catenin pathway.
    Type: Application
    Filed: August 27, 2004
    Publication date: March 17, 2005
    Applicant: Choongwae Pharma Corporation
    Inventors: Michael Kahn, SeWoong Oh, DaeHoon Kim, JongRyul Ha, Katayoon Hojjati-Emami
  • Patent number: 6762185
    Abstract: The invention involves compounds having the general formula (I) as described in the claims and pharmaceutical compositions comprising such compounds. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: July 13, 2004
    Assignee: Choongwae Pharma Corporation
    Inventors: Michael Kahn, Masakatsu Eguchi, Sung Hwan Moon, Jae Uk Chung, Kwang Won Jeong